The House Labor, Health and Human Services funding bill is scheduled to be considered by the House Rules Committee today.
U.S. Representative Tom Cole Receives National Distinguished Advocacy Award for Championing Lifesaving Cancer Research
Award is Highest Honor Presented by the American Cancer Society Cancer Action Network
WASHINGTON, D.C. – September 20, 2023 – United States Representative Tom Cole received the National Distinguished Advocacy Award this week, the most prestigious award presented by the American Cancer Society Cancer Action Network (ACS CAN), in recognition of his significant contribution in the fight against cancer to increase research funding.
ACS CAN, the advocacy affiliate of the American Cancer Society, presents the annual award to select lawmakers who demonstrate outstanding leadership in the area of cancer-related public policy advocacy.
“Representative Cole has repeatedly distinguished himself as a leader and true advocate on cancer advocacy issues, particularly through his commitment to increased biomedical research funding,” said Lisa Lacasse, president of ACS CAN. “His introduction of the Strengthen the Pediatric Research Initiative Act, to provide additional funding for childhood cancer research, is a true testament of his commitment to save lives from pediatric cancer. ACS CAN appreciates his steadfast leadership in investing in cancer research to improve public health nationwide.”
“Representative Cole is a true cancer leader”, said Howie Jackson, cancer survivor and ACS CAN Oklahoma CD-04 ACT Lead volunteer. “His commitment to providing additional funding for child cancer research is a testament to the value he sees in our next generation of Oklahomans.”
The award was presented on Sept. 19 as part of the annual ACS CAN Leadership Summit and Lobby Day. Nearly 700 cancer patients, survivors and their loved ones met with their elected officials to urge them to support policies that increase funding for cancer research and prevention programs and address barriers that prevent diverse populations from enrolling in clinical trials.